Zynteglo badge 1st Approved for Gene Therapy 

Transfusion-dependent
β-thalassaemia (TDT)

People arranged in a double-helical formation on a field releasing blood bags into the air like balloons
FOR YOUR PATIENTS ≥12 YEARS OF AGE
WITH TRANSFUSION-DEPENDENT β-THALASSAEMIA (TDT) WHO DO NOT HAVE A β0/ β0 GENOTYPE AND WHO DO NOT HAVE AN HLA-MATCHED RELATED DONOR1*

Help them let go of
chronic transfusions1

ZYNTEGLO (autologous CD34+ cells encoding βA-T87Q-globin gene†) is the first and only one-time gene therapy for transfusion-dependent β-thalassaemia that gives patients the potential to reach transfusion independence2‡

See how ZYNTEGLO works
 
The majority of patients* treated with ZYNTEGLO achieved transfusion independence1
Zynteglo Efficacy
No cases of lentiviral vector (LVV)-mediated insertional mutagenesis resulting in oncogenesis1
Zynteglo Safety
For TDT patients ≥12 years of age who do not have a β0/β0 genotype and who do not have an HLA-matched related donor1
Patient Identification

*Patients are eligible for assessment of transfusion independence if they have completed the parent study or achieved transfusion independence or will not achieve transfusion independence in the parent study.1

*INDICATION1

ZYNTEGLO is indicated for the treatment of patients 12 years and older with transfusion-dependent β-thalassaemia (TDT) who do not have a β0/β0 genotype, for whom haematopoietic stem cell (HSC) transplantation is appropriate but a human leukocyte antigen (HLA)–matched related HSC donor is not available.